Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HIMS
- Rev/Share 8.038
- Book/Share 2.4743
- PB 22.8593
- Debt/Equity 0.1154
- CurrentRatio 1.5942
- ROIC 0.2452
- MktCap 12186078240.0
- FreeCF/Share 1.0821
- PFCF 50.7295
- PE 76.3753
- Debt/Assets 0.0711
- DivYield 0
- ROE 0.3597
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | HIMS | TD Cowen | Buy | Hold | -- | $30 | April 29, 2025 |
| Downgrade | HIMS | Morgan Stanley | Overweight | Equal Weight | $42 | $60 | Feb. 18, 2025 |
| Downgrade | HIMS | Citigroup | Neutral | Sell | $24 | $25 | Jan. 10, 2025 |
| Initiation | HIMS | BTIG Research | -- | Buy | -- | $35 | Jan. 7, 2025 |
| Initiation | HIMS | Morgan Stanley | -- | Overweight | -- | $42 | Dec. 17, 2024 |
| Initiation | HIMS | Needham | -- | Buy | -- | $24 | Aug. 22, 2024 |
News
Hims to cut 4% of workforce amid ban on weight-loss drug copies
Published: May 30, 2025 by: Reuters
Sentiment: Negative
Telehealth platform Hims & Hers said on Friday it will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy.
Read More
Hims & Hers vs. Amwell: Which Telehealth Stock Is the Better Buy?
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS targets personalized, AI-powered care with bold obesity moves, while AMWL bets on system-wide integration via Converge and top-tier health alliances. Who wins? Let's see.
Read More
Hims & Hers Health Stock: After Doubling, It May Be Too Late To Buy
Published: May 29, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health shows strong growth in subscribers, revenue, and profitability, driven by expanding offerings and strategic partnerships, especially in weight loss and dermatology. HIMS posted stellar Q1 FY 2025: Revenue +110%, EBITDA +181%, EPS +300%. Growth fueled by ~2.4M subscribers and $84 average monthly revenue per user. Management's ambitious 2030 strategy leverages AI, new specialties, and global expansion, aiming for significant top-line and EPS growth.
Read More
Hims & Hers Stock Falls Despite the Latest Wegovy Availability Offer
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
HIMS launches six-month Wegovy access at $549/month, aiming to expand affordable obesity care with holistic weight loss solutions.
Read More
Cautious? Risky? Our Volatility Scorecard Can Help
Published: May 27, 2025 by: Schaeffers Research
Sentiment: Neutral
Our volatility scorecard has a pretty good feel for the market right now.
Read More
Avoid These Dividend Disasters Before It's Too Late
Published: May 23, 2025 by: Seeking Alpha
Sentiment: Negative
Dividend stocks are facing many big risks. The high interest rates, trade war, and AI revolution could lead to many dividend cuts. I discuss what this all means for dividend investors.
Read More
Hims & Hers Introduces 6-Month Wegovy® New Customer Offer
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at a new, affordable price, making proven obesity care and treatments more accessible, more affordable, and more connected for millions of Americans. “We are always looking for long-term, sustainable ways to increase access to care for our customers,” said Andrew Dudum, CEO and co-founder of Hims & Hers. “This is another example of how.
Read More
Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?
Published: May 22, 2025 by: MarketBeat
Sentiment: Neutral
When investors choose to risk their capital in an individual company, they must be aware that the stock market isn't the one-sided machine it used to be a few decades ago. Thanks to the flow of information and availability in the digital space, today's market has become more interconnected than ever before.
Read More
5 Single-Stock ETFs That Doubled in a Month
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive
We have highlighted five single-stock ETFs that have doubled over the past month amid a historic Wall Street comeback.
Read More
Hims & Hers: After A Bout Of Uncertainty, Upside Remains
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers continues to deliver strong subscriber and revenue growth, with Q1 2025 revenue up 111% year-over-year and operating leverage improving. The business model's shift to a subscription platform with personalized care unlocks significant long-term free cash flow and expansion opportunities. Management's guidance and execution support a path to $6.5B in revenue by 2030, with my valuation thesis still intact and suggesting undervaluation.
Read More
Hims & Hers Stock Chart Points to Strong Bullish Continuation
Published: May 20, 2025 by: MarketBeat
Sentiment: Positive
Hims and Hers, Inc. NYSE: HIMS shows strongly bullish signs that begin and end with the stock price action. It reflects volatility, but the bias is upward with rising support and the most recent swing, a bullish rebound, looks very strong within the pattern.
Read More
Here's Why You Should Add Hims & Hers Stock to Your Portfolio Now
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers leads with AI-powered, personalized health plans (over 70% of new users opt in). Recurring revenues surge as tailored care drives loyalty.
Read More
Hims & Hers Stock Declines 3.1% in 3 Months: Is it a Buy Now?
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Negative
HIMS is expanding its health and wellness products and services and increasing its focus on AI to solidify its footing. However, macro challenges may hurt performance.
Read More
Buy Amazon (AMZN), Shopify (SHOP) and Hims & Hers (HIMS) in May And Hold Forever
Published: May 16, 2025 by: 24/7 Wall Street
Sentiment: Neutral
There's a well-known saying in the investing world, which advises investors to “sell in May and go away.
Read More
Bet on Winning DuPont Analysis & Pick 3 Top Stocks
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Do you have more faith in DuPont analysis than simple ROE calculation? Tap EverQuote (EVER), Hims & Hers Health (HIMS) and Sprouts Farmers Market (SFM).
Read More
Hims & Hers: Growth, Strategic Partnerships, And Operational Leverage (Upgrade)
Published: May 16, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health's rapid revenue and subscriber growth, plus improving cash generation, highlight strong business momentum and brand strength. Gross margins have declined due to lower-margin obesity products, but SG&A as a percentage of revenue is improving, supporting better operating leverage. The recent Novo Nordisk collaboration and capital raise position Hims for expansion, though reliance on GLP-1 drugs and competition are key risks.
Read More
Hims & Hers Health, Inc. (HIMS) is a Great Momentum Stock: Should You Buy?
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Hims & Hers Health, Inc. (HIMS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Top Health & Fitness Stocks to Buy for the Wellness Boom
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
The health and fitness boom is fueling demand for gyms, nutrition, and wellness services. Stocks like SFM, HIMS and DXCM are well-positioned to benefit.
Read More
Cautious? Risky? Our Volatility Scorecard Can Help
Published: May 13, 2025 by: Schaeffers Research
Sentiment: Neutral
Subscribers to Chart of the Week received this commentary on Sunday, May 11.
Read More
Hims & Hers Health Stock: A Rare High-Growth Value Play In Plain Sight
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Positive
Rarely I see high-growth, value plays in the market. I think Hims & Hers Health is such a rare case: a world-class, high-growth company still being valued as a risky startup. A DCF model based on 2030 guidance suggests a $64 fair value per share, with potential to far exceed that price due to management's conservative guidance. I think HIMS stock's fair value is above $84 per share, with potential to upwards of $300 per share in a bullish case scenario (2030 DCF model).
Read More
Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Five Health and Fitness stocks to buy now are: SFM, DXCM, HIMS, UNFI, GDRX.
Read More
Hims & Hers: Still Undervalued For These 2 Reasons
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Positive
Hims' operating leverage was outstanding at 5:1 over revenue growth. This is irrefutable proof of a scalable business. Hims' new TAMs should provide billions to the top line, hundreds of millions to the bottom, and dollars to EPS. Hims is likely a decade-plus ahead of competitors at this point with 'The Hims Trinity.'
Read More
Hims & Hers: Short-Lived Turbulence To Be Followed By New Phase Of Profitable Growth
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers delivered impressive Q1 2025 results, with 111% y/y revenue growth and 38% y/y subscriber growth, driven by strong uptake of personalized GLP-1 offerings. Despite a projected Q2 revenue decline due to product transitions, management reaffirmed full-year 2025 revenue guidance of $2.3–2.4B and raised adj. EBITDA guidance to $295–335M. Long-term growth prospects remain strong, with a target of $6.5B+ revenue and $1.3B+ adj. EBITDA by 2030, driven by TAM penetration, new specialties, and AI integration.
Read More
Hims & Hers: Wegovy Deal Opens New Growth Chapter - Missed The Rally? Selling Puts Could Yield 30%
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health rebounded from a 60% stock drop by partnering with Novo Nordisk, offering Wegovy at a competitive price, boosting accessibility and growth. Q1 earnings were exceptional with 111% YoY revenue growth and a 345% increase in net income, highlighting a sustainable and resilient business model. The company's personalized healthcare approach and new product launches, like low testosterone and menopause support, are driving subscriber growth and higher revenue per subscriber.
Read More
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Read More
Hims & Hers Health, Inc. Prices Upsized $870.0 Million Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $870,000,000 aggregate principal amount of 0.00% convertible senior notes due 2030 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced of.
Read More
Hims & Hers Stock's 100% Surge Is Squeezing Shorts And It Might Just Be Getting Started
Published: May 08, 2025 by: Benzinga
Sentiment: Positive
If short sellers were hoping for a flop from Hims & Hers Health Inc. HIMS, they may want to check their risk management settings. The telehealth disruptor dropped first-quarter earnings after the bell on Monday, and instead of the crash shorts were counting on, the market got a bullish cocktail: strong guidance, solid revenue growth and a headline-making partnership with Novo Nordisk A/S NVO.
Read More
Hims & Hers: The Road To Blue Chip Status
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Positive
Personalized subscribers grew 136% YoY, reflecting a fundamental shift towards precision medicine. Despite declining gross margins, HIMS achieved 13pp of operating leverage in Q1. This is by far HIMS' best quarter to date. The markets need to put some respect on Andrew Dudum and his world-class team.
Read More
Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply pe.
Read More
Hims & Hers: 2030 Guidance Indicates Big Upside
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Positive
Management's 2030 guidance includes $6.5 billion in revenue and $1.3 billion in adjusted EBITDA, focusing on personalized healthcare and geographic expansion. Anticipating management's guidance for 2025 and 2030, Hims & Hers could be undervalued by up to 62%. Apart from the guidance, the company needs to achieve growth rates in the mid-teens% to justify the current valuation.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Household & Personal Products
- CEO Mr. Andrew Dudum
- Employees 1637